Government-Owned Inventions; Availability for Licensing, 66910-66912 [E8-26787]
Download as PDF
<![CDATA[
66910
Federal Register / Vol. 73, No. 219 / Wednesday, November 12, 2008 / Notices
Licensing Contact: Kevin W. Chang,
PhD; 301–435–5018;
changke@mail.nih.gov
Collaborative Research Opportunity:
The National Cancer Institute, Center for
Cancer Research, Nanobiology Program
is seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize the
use of hydrophobic crosslinkers for their
use in vaccine development. Interested
collaborators are also invited to provide
statements for proposed in vitro or in
vivo studies using various enveloped
viruses. Please contact John D. Hewes,
PhD at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
mstockstill on PROD1PC66 with NOTICES
Indoline Compounds for the Treatment
of Spinal Muscular Atrophy (SMA) and
Other Diseases
Description of Technology: With the
goal to treat SMA in patients, several
indoline compounds were made and
tested for activity. Tests in cells
demonstrate that these drugs increased
the levels of active SMN protein. This
is encouraging since low levels of this
protein appears to be the cause of
neuronal death that leads to SMA. This
class of compounds appears to operate
via read-through of a non-sense stopcodon to produce full length, functional
protein in SMA models. This
mechanism may have utility in several
other neurological disorders, including
cystic fibroses and Duchene’s Muscular
Dystrophy.
In addition, these compounds have
also been shown to increase the
concentration of a glutamate transporter
protein in cells, which acts to recover
glutamate back into neurons after
release. Since the toxic effect of
unrecovered excess glutamate is
observed in many notorious
neurological conditions, these
compounds have potential for
prevention or treatment.
Applications:
• Treatment of SMA in infants and
children.
• Treat genetic-based diseases that
result from a premature stop of protein
synthesis such as muscular dystrophy
and cystic fibrosis.
• Treating or preventing neurological
diseases presenting glutamate toxicity
like multiple sclerosis, Parkinson’s,
Alzheimer’s, amyotrophic lateral
sclerosis (ALS), or others.
Market:
• SMA is a rare genetic disease
estimated to affect 1 in 6,000 births and
leading genetic cause of death in infants
and toddlers.
VerDate Aug<31>2005
18:30 Nov 10, 2008
Jkt 217001
• Over 25,000 Americans are believed
to suffer from SMA and the market size
has been estimated between $250
million and $750 million.
Development Status: Pre-clinical,
Toxicology and Safety Studies, Animal
Models (Dogs and Primates).
Inventors: Jill E. Heemskerk (NINDS)
et al.
Related Publication: MR Lunn, DE
Root, AM Martino, SP Flaherty, BP
Kelley, DD Coovert, AH Burghes, NT
Man, GE Morris, J Zhou, EJ Androphy,
CJ Sumner, BR Stockwell. Indoprofen
upregulates the survival motor neuron
protein through a cyclooxygenaseindependent mechanism. Chem Biol.
2004 Nov;11(11):1489–1493.
Patent Status:
• U.S. Provisional Application No.
60/975,675 filed 27 Sept 2007 (HHS
Reference No. E–187–2007/0–US–01);
• PCT Application No. PCT/US2008/
077936 filed 26 Sep 2008 (HHS
Reference No. E–187–2007/0–PCT–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Norbert Pontzer,
PhD, JD; 301–435–5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Neurological
Disorders and Stroke is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize drugs for the treatment of
SMA, as well as investigation into novel
uses for these indoline compounds.
Please contact Dr. Melissa Maderia at
maderiam@mail.nih.gov or 301–451–
3943 for more information.
Discovery of and Use of Fragments of
DOC1 as Antiangiogenic and Antitumor
Therapy
Description of Technology: This
invention describes small cDNA
fragments of the coding region for wild
type filamin A interacting protein 1-like
(FILIP1L), previously known as downregulated in ovarian cancer 1-like
(DOC1) and variant 2 of FILIP1L genes
that encode proteins that result in the
inhibition of cell migration and motility,
induce cell apoptosis and inhibit cell
proliferation. These effects can be seen
on endothelial cells and on tumor cells.
These coding sequences have
successfully been delivered to
endothelial cells and tumor cells both in
vitro and in vivo, and have
demonstrated significant anti-tumor
activity. In addition, the inventors have
for the first time expressed the
recombinant protein and developed
antibodies to detect the protein
fragments by Western, ELISA and
immunohistochemistry. The
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
significance of this invention is that it
could provide for a series of new anticancer therapeutics and for the
diagnostic means to follow their
expression levels.
Applications: This invention could
provide new anti-cancer therapeutics
and diagnostics.
Market:
• An estimated 1,444,920 new cancer
diagnoses in the U.S. in 2007.
• 600,000 deaths caused by cancer in
the U.S. in 2006.
• Cancer is the second leading cause
of death in the U.S.
• Cancer drug market will likely
double to $50 billion in 2010 from $25
billion in 2006.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Steven K. Libutti et al.
(NCI).
Relevant Publication: Mijung Kwon et
al. Functional characterization of
filamin A interacting protein 1-like, a
novel candidate for antivascular cancer
therapy. Cancer Res. 2008 Sep
15;68(18):7332–7341.
Patent Status: U.S. Provisional
Application No. 61/005,363 filed 03 Dec
2007 (HHS Reference No. E–166–2007/
0-US–01).
Licensing Status: Available for
exclusive and non-exclusive license.
Licensing Contact: Adaku
Nwachukwu, JD; 301–435–5560;
madua@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute Hatfield
Clinical Research Center is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize Discovery of and Use of
Fragments of DOC1 as Antiangiogenic
and Antitumor Therapy. Please contact
John D. Hewes, PhD at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Dated: November 3, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–26786 Filed 11–10–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
E:\FR\FM\12NON1.SGM
12NON1
Federal Register / Vol. 73, No. 219 / Wednesday, November 12, 2008 / Notices
ACTION:
Notice.
mstockstill on PROD1PC66 with NOTICES
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Therapeutic Targeting of CSN5, a
Negative Regulator of p53 and p27, in
Human Hepatocellular Carcinoma
Description of Technology:
Hepatocellular carcinoma (HCC)
represents an extremely poor prognostic
cancer that remains one of the most
common and aggressive malignancies
worldwide. Elevated expression of
COP9 complex homolog subunit 5
(CSN5) in early HCC indicates that
CSN5 is one of the early markers of
malignant conversion. COP9 complex
homolog subunit 5 (CSN5) is a
multifunctional protein that interacts
with a variety of proteins and targets
p53 for cell degradation.
Available for licensing are CSN5
siRNAs and nucleic acid-lipid siRNA
particles as cancer therapies. HCC cells
treated with CSN5 siRNAs inhibited
HCC progression and increased
apoptosis in vitro and in vivo suggesting
that CSN5 is an effective target for the
development of cancer treatments.
Applications:
• siRNA cancer therapeutics.
• Nucleic acid-lipid siRNA particles
for targeted drug delivery.
• Method to treat cancer.
Development Status: Early stage of
development.
Market:
• HCC is the most frequent primary
malignant tumor of the liver with a
world incidence of 1 million new cases
per year.
• The global cancer therapeutic
market is expected to grow from $23.1
billion in 2004 to $60.6 billion in 2011.
The targeted therapy segment is
providing the growth of the entire
market with an expected compound
VerDate Aug<31>2005
18:30 Nov 10, 2008
Jkt 217001
annual growth rate of 24.1 percent for
2004–2011.
Inventors: Snorri Thorgeirsson (NCI),
Yun-Han Lee (NCI), et al.
Patent Status: U.S. Provisional
Application No. 61/045,251 filed 15 Apr
2008 (HHS Reference No. E–174–2008/
0–US–01).
Publication: JS Lee et al.
Classification and prediction of survival
in hepatocellular carcinoma by gene
expression profiling. Hepatology 2004
Sept;40(3):667–676.
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Computer Aided Scoring and Analysis
(CASA) for Rapid and Robust Detection
of Biological Molecules in Tissue
Microarrays
Description of Technology: Tissue
Microarray (TMA) technology is a
technique that allows tissue samples to
be miniaturized and biologically
characterized. The results can be stored
digitally and analyzed manually for the
expression of biological molecules
which can permit the diagnosis or
prognosis of disease. Despite its
practical use, the current method of
manually analyzing TMA samples is
subjective and lacks the standardization
and concordance needed to support
consistent interpretation of the results.
This leads to a low correlation in the
results obtained amongst different
laboratories and detection agents.
The current invention, Computer
Aided Scoring and Analysis (CASA),
provides a means of rapidly and
consistently analyzing the expression
patterns of biological molecules in large
quantities of tissue samples. This
software uses novel algorithms which
normalize the pixel data obtained from
digital images of the samples,
statistically determines which biological
molecules are diagnostic markers for the
disease, and compares these data to
normal, as well as diseased or abnormal
tissue samples, to diagnose or predict
susceptibility to the disease. In some
applications, two or more biological
molecules can be simultaneously
screened or identified using two or more
detection agents making the CASA
system amenable to methods such as
cluster analysis. This type of analysis
can not only identify groups of antigens
that are associated with a disease, but
can also combine this information with
characteristics of the patient population,
such as age, gender or ethnicity to
achieve a predictive output. The CASA
system can analyze data from a broad
range of detection agents such as
antibodies, radionuclides, dyes and
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
66911
quantum dots making it a very attractive
tool for high throughput TMA analysis.
The system has already been used
successfully for the diagnosis and
prognosis of non-small cell lung cancer
in tissue samples and can be adapted for
use in many diseases where changes in
the expression of one or more biological
molecules will to be detected.
Applications:
• Large scale diagnosis of tissue
expression patterns of biological
molecules.
• Rapid, robust tissue diagnosis or
prognosis of disease.
• Compatible with wide range of
detection agents.
Development Status: Early Stage.
Inventors: Abbas Shakoori and Jin Jen
(NCI).
Patent Status: U.S. Provisional
Application No. 61/034,868 filed 07 Mar
2008 (HHS Reference No. E–126–2008/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jeffrey A. James,
PhD; 301–435–5474;
jeffreyja@mail.nih.gov.
Predictive Test for Age-Related
Macular Degeneration in Asymptomatic
Individuals
Description of Technology: Agerelated macular degeneration (ARMD) is
the leading cause of severe, irreversible
vision loss for those over the age of fifty
in the United States and in other
developed countries. Thirteen million
Americans over the age of forty have
ARMD. ARMD is caused by the
deterioration of the central area of the
retina, or macula, resulting in a loss of
central vision. This disease is believed
to be a multigenic disorder, and is
triggered by environmental factors such
as smoking, age or diet in genetically
susceptible individuals.
The present invention describes a
highly predictive genetic test for
universal practical clinical use to
identify individuals at increased risk for
ARMD. It comprises a rapid, accurate
and affordable genetic screen, utilizing
DNA microarray technology on a single
chip. Sixteen genes are screened for 90
mutations/polymorphisms associated
with ARMD, with a high predictive
power (up to 92.7%) to identify
asymptomatic carriers at risk. Accurate
prediction of genetic susceptibility to
this disorder will allow interventions to
protect at-risk individuals.
Applications:
• Method to diagnose ARMD.
• Diagnostic kit to identify
asymptomatic individuals at risk for
ARMD.
• Method to identify genetic factors
in an affected individual, aiding in the
E:\FR\FM\12NON1.SGM
12NON1
66912
Federal Register / Vol. 73, No. 219 / Wednesday, November 12, 2008 / Notices
development of a tailored therapeutic
plan.
• Provide genetic epidemiologic data
to elucidate the role of genetic factors in
the progression of the disease.
Advantage: Easy, rapid highthroughput method to diagnose ARMD.
Development Status: This technology
requires analytic validation before
commercialization.
Market: There are an estimated 15
million cases of age-related macular
degeneration in the United States, and
50 million cases worldwide.
Inventors: Cigdem F. Dogulu, Owen
M. Rennert, Wai-Yee Chan (NICHD)
Patent Status:
• U.S. Patent Application No. 12/
089,694 filed 09 Apr 2008 (HHS
Reference No. E–023–2006/0–US–07).
• Australian Patent Application No.
2006311966 filed 02 Nov 2006 (HHS
Reference No. E–023–2006/0–AU–03).
• Canadian Patent Application No.
2,627,686 filed 02 Nov 2006 (HHS
Reference No. E–023–2006/0–CA–04).
• European Patent Application No.
06836855.4 filed 02 Nov 2006 (HHS
Reference No. E–023–2006/0–CA–04).
• Japanese Patent Application No.
2008–539046 filed 01 May 2008 (HHS
Reference No. E–023–2006/0–JP–06).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The NICHD Section on Clinical
Genomics is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize Method Evolved for
Recognition and Testing of Age-Related
Macular Degeneration (MERT–ARMD).
Please contact John D. Hewes, PhD at
301–435–3121 or hewesj@mail.nih.gov
for more information.
Dated: November 3, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–26787 Filed 11–10–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on PROD1PC66 with NOTICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
VerDate Aug<31>2005
18:30 Nov 10, 2008
Jkt 217001
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
Radiation Induced and Targeted
Chemotherapy
Description of Technology: The
invention relates to a novel method of
targeted chemotherapy for the treatment
of cancer using hydrophobic
photoactivatable compounds like 1,5iodoanpthylazide (INA) and its
analogues. The invention evolved from
the discovery that electron dense atomcontaining photoactivatable compounds
can be activated by radiation (i.e., by xrays and/or ultrasound) to form reactive
intermediates that are highly toxic to
living cells. Such compounds are
termed ‘‘radiation-activatable’’
compounds. These radiation-activatable
compounds do not become toxic until
activated by radiation which allows for
the targeting of the toxic compound by
irradiation. Preliminary in vitro data
show that INA and its derivatives can
quickly and efficiently kill tumor cell
lines upon irradiation.
Applications: Cancer Treatment.
Advantages: Novel method of cancer
treatment.
Development Status: In vitro data can
be provided upon request.
Market: Cancer Therapy.
Inventors: Yossef Raviv et al. (NCI).
Patent Status: U.S. Provisional
Application No. 61/026,654 filed 06 Feb
2008 (HHS Ref. No. E–256–2007/0-US–
01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Kevin W. Chang,
PhD, 301–435–5018,
changke@mail.nih.gov.
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
Small-Molecule Modulators of the
Thyroid-Stimulating Hormone (TSH)
Receptor
Description of Technology: The
thyroid gland plays a major role in the
body, secreting hormones that regulate
the metabolic rate, production of other
hormones, and the growth and
maturation of body tissues. Thyroid
disorders affect energy metabolism,
neurological state, fertility,
cardiovascular condition, and other
body functions. In patients with
hyperthyroidism, or an overactive
thyroid gland, the disease is often
caused by autoimmune over-stimulation
of the thyroid gland (Graves’ disease), or
by thyroid tumors. Drugs currently used
for short-term treatment of
hyperthyroidism inhibit synthesis of
thyroid hormones, although long-term
treatment usually requires removal of
the thyroid gland by surgery or
administration of radioiodine.
Hypothyroidism, or an underactive
thyroid gland, can be caused by
autoimmune disease, atrophy of the
thyroid gland, or through a deficiency of
thyroid-stimulating hormone (TSH).
TSH, produced by the pituitary gland,
binds to the TSH receptor in the thyroid
to stimulate thyroid hormone
production. Hypothyroidism is typically
treated by direct replacement of the
thyroid hormones.
The inventors have discovered a
series of low-molecular weight
compounds that act as TSH receptor
antagonists (inhibitors) or agonists
(activators). Antagonists of the TSH
receptor could be used to treat
hyperthyroidism, with the advantage of
directly downregulating the TSH
receptor, rather than inhibiting thyroid
hormone synthesis. Agonists of the TSH
receptor could be used to monitor
thyroid activity and potential cancer
recurrence in patients who have been
treated for thyroid cancer, and may also
be useful for treatment of certain forms
of hypothyroidism. Additionally, some
compounds in this family may be useful
for treatment of fertility and
reproductive disorders involving the
luteinizing hormone/
choriogonadotropin (LH/CG) receptor
and the follicle-stimulating hormone
(FSH) receptor, which are structurally
related to the TSH receptor.
Applications:
• Development of therapeutics for
hyperthyroidism or hypothyroidism.
• Development of diagnostic tools for
evaluation of thyroid cancer patients.
• Development of therapeutics for
infertility.
Market: Approximately 1 in 13
Americans suffers from a thyroid
E:\FR\FM\12NON1.SGM
12NON1
]]>Agencies
[Federal Register Volume 73, Number 219 (Wednesday, November 12, 2008)]
[Notices]
[Pages 66910-66912]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-26787]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
[[Page 66911]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Therapeutic Targeting of CSN5, a Negative Regulator of p53 and p27, in
Human Hepatocellular Carcinoma
Description of Technology: Hepatocellular carcinoma (HCC)
represents an extremely poor prognostic cancer that remains one of the
most common and aggressive malignancies worldwide. Elevated expression
of COP9 complex homolog subunit 5 (CSN5) in early HCC indicates that
CSN5 is one of the early markers of malignant conversion. COP9 complex
homolog subunit 5 (CSN5) is a multifunctional protein that interacts
with a variety of proteins and targets p53 for cell degradation.
Available for licensing are CSN5 siRNAs and nucleic acid-lipid
siRNA particles as cancer therapies. HCC cells treated with CSN5 siRNAs
inhibited HCC progression and increased apoptosis in vitro and in vivo
suggesting that CSN5 is an effective target for the development of
cancer treatments.
Applications:
siRNA cancer therapeutics.
Nucleic acid-lipid siRNA particles for targeted drug
delivery.
Method to treat cancer.
Development Status: Early stage of development.
Market:
HCC is the most frequent primary malignant tumor of the
liver with a world incidence of 1 million new cases per year.
The global cancer therapeutic market is expected to grow
from $23.1 billion in 2004 to $60.6 billion in 2011. The targeted
therapy segment is providing the growth of the entire market with an
expected compound annual growth rate of 24.1 percent for 2004-2011.
Inventors: Snorri Thorgeirsson (NCI), Yun-Han Lee (NCI), et al.
Patent Status: U.S. Provisional Application No. 61/045,251 filed 15
Apr 2008 (HHS Reference No. E-174-2008/0-US-01).
Publication: JS Lee et al. Classification and prediction of
survival in hepatocellular carcinoma by gene expression profiling.
Hepatology 2004 Sept;40(3):667-676.
Licensing Status: Available for non-exclusive licensing.
Licensing Contact: Jennifer Wong; 301-435-4633;
wongje@mail.nih.gov.
Computer Aided Scoring and Analysis (CASA) for Rapid and Robust
Detection of Biological Molecules in Tissue Microarrays
Description of Technology: Tissue Microarray (TMA) technology is a
technique that allows tissue samples to be miniaturized and
biologically characterized. The results can be stored digitally and
analyzed manually for the expression of biological molecules which can
permit the diagnosis or prognosis of disease. Despite its practical
use, the current method of manually analyzing TMA samples is subjective
and lacks the standardization and concordance needed to support
consistent interpretation of the results. This leads to a low
correlation in the results obtained amongst different laboratories and
detection agents.
The current invention, Computer Aided Scoring and Analysis (CASA),
provides a means of rapidly and consistently analyzing the expression
patterns of biological molecules in large quantities of tissue samples.
This software uses novel algorithms which normalize the pixel data
obtained from digital images of the samples, statistically determines
which biological molecules are diagnostic markers for the disease, and
compares these data to normal, as well as diseased or abnormal tissue
samples, to diagnose or predict susceptibility to the disease. In some
applications, two or more biological molecules can be simultaneously
screened or identified using two or more detection agents making the
CASA system amenable to methods such as cluster analysis. This type of
analysis can not only identify groups of antigens that are associated
with a disease, but can also combine this information with
characteristics of the patient population, such as age, gender or
ethnicity to achieve a predictive output. The CASA system can analyze
data from a broad range of detection agents such as antibodies,
radionuclides, dyes and quantum dots making it a very attractive tool
for high throughput TMA analysis.
The system has already been used successfully for the diagnosis and
prognosis of non-small cell lung cancer in tissue samples and can be
adapted for use in many diseases where changes in the expression of one
or more biological molecules will to be detected.
Applications:
Large scale diagnosis of tissue expression patterns of
biological molecules.
Rapid, robust tissue diagnosis or prognosis of disease.
Compatible with wide range of detection agents.
Development Status: Early Stage.
Inventors: Abbas Shakoori and Jin Jen (NCI).
Patent Status: U.S. Provisional Application No. 61/034,868 filed 07
Mar 2008 (HHS Reference No. E-126-2008/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jeffrey A. James, PhD; 301-435-5474;
jeffreyja@mail.nih.gov.
Predictive Test for Age-Related Macular Degeneration in Asymptomatic
Individuals
Description of Technology: Age-related macular degeneration (ARMD)
is the leading cause of severe, irreversible vision loss for those over
the age of fifty in the United States and in other developed countries.
Thirteen million Americans over the age of forty have ARMD. ARMD is
caused by the deterioration of the central area of the retina, or
macula, resulting in a loss of central vision. This disease is believed
to be a multigenic disorder, and is triggered by environmental factors
such as smoking, age or diet in genetically susceptible individuals.
The present invention describes a highly predictive genetic test
for universal practical clinical use to identify individuals at
increased risk for ARMD. It comprises a rapid, accurate and affordable
genetic screen, utilizing DNA microarray technology on a single chip.
Sixteen genes are screened for 90 mutations/polymorphisms associated
with ARMD, with a high predictive power (up to 92.7%) to identify
asymptomatic carriers at risk. Accurate prediction of genetic
susceptibility to this disorder will allow interventions to protect at-
risk individuals.
Applications:
Method to diagnose ARMD.
Diagnostic kit to identify asymptomatic individuals at
risk for ARMD.
Method to identify genetic factors in an affected
individual, aiding in the
[[Page 66912]]
development of a tailored therapeutic plan.
Provide genetic epidemiologic data to elucidate the role
of genetic factors in the progression of the disease.
Advantage: Easy, rapid high-throughput method to diagnose ARMD.
Development Status: This technology requires analytic validation
before commercialization.
Market: There are an estimated 15 million cases of age-related
macular degeneration in the United States, and 50 million cases
worldwide.
Inventors: Cigdem F. Dogulu, Owen M. Rennert, Wai-Yee Chan (NICHD)
Patent Status:
U.S. Patent Application No. 12/089,694 filed 09 Apr 2008
(HHS Reference No. E-023-2006/0-US-07).
Australian Patent Application No. 2006311966 filed 02 Nov
2006 (HHS Reference No. E-023-2006/0-AU-03).
Canadian Patent Application No. 2,627,686 filed 02 Nov
2006 (HHS Reference No. E-023-2006/0-CA-04).
European Patent Application No. 06836855.4 filed 02 Nov
2006 (HHS Reference No. E-023-2006/0-CA-04).
Japanese Patent Application No. 2008-539046 filed 01 May
2008 (HHS Reference No. E-023-2006/0-JP-06).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301-435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The NICHD Section on Clinical
Genomics is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize Method Evolved for Recognition and Testing of Age-Related
Macular Degeneration (MERT-ARMD). Please contact John D. Hewes, PhD at
301-435-3121 or hewesj@mail.nih.gov for more information.
Dated: November 3, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-26787 Filed 11-10-08; 8:45 am]
BILLING CODE 4140-01-P
